Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

Fig. 2

Genome alterations and HRDs in TNBC patients. A Mutation profile of high-frequency mutation genes in patients (top 30). B Distribution of HRD score and mutational signature 3 activity in patients with HR deficiency and HR proficiency. The patients with BRCA1/BRCA2 mutations highlighted in blue and orange colours, respectively. C Box plot showing the distribution of mutational signature 3 exposure in patients with HR deficiency (HR-D) and HR proficiency (HR-P). SBS3, single-base substitution signature 3. P-value was calculated by the Wilcoxon rank-sum test. D, E The bar graph showing the relationship between HRD status and HRR gene mutation (D), BRCA1 promoter methylation/HRDetect score and HRDetect scorehi (≥ 0.7) (E). P-value was calculated by Fisher’s exact test

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us